Alunacedase alfa is a recombinant and soluble glycosylated form of human ACE2. This recombinant version of the enzyme has antihypertensive and potential antineoplastic activities.
- Mechanism
- Curator reviewed
Angiotensin Converting Enzyme 2 (ACE2) degrades Angiotensin II (known as Ang1-8) into Ang1-7. Angiotensin II exerts actions like inflammation, ROS production, and vasoconstriction, and is implicated in acute respiratory distress syndrome (ARDS). Its conversion to Ang1-7 by ACE2 contrasts these actions as Ang1-7 promotes vasodilation, anti-inflammation, and NO release -- attenuating tissue injury which includes ARDS-associated injury. Additional administration of ACE2 by way of a recombinant protein is thought to aid in conversion of excessive Ang1-8 associated with ARDS into Ang1-7, and help reduce the damaging effects of the renin-angiotensin system. This compound, as such, is being investigated for lung injury and ARDS associated with COVID-19.
- Also known as
- Recombinant Human Angiotensin-Converting Enzyme 2 · rhACE2
- Code names
- APN-01 · GSK-2586881
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with Alunacedase alfa, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account